Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease.
Virani SS, Woodard LD, Chitwood SS, Landrum CR, Urech TH, Wang D, Murawsky J, Ballantyne CM, Petersen LA.
Am Heart J. 2011 Oct;162(4):725-732.e1. Epub 2011 Aug 25.
Related citations
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.
Dansky HM, Bloomfield D, Gibbons P, Liu S, Sisk CM, Tribble D, McKenney JM, Littlejohn TW 3rd, Mitchel Y.
Am Heart J. 2011 Oct;162(4):708-16. Epub 2011 Sep 1.
Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, Mehran R, Stone GW.
Am Heart J. 2011 Oct;162(4):663-70.
Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
Yoon HS, Kim SH, Kim JK, Ko SH, Ko JE, Park SJ, Park MG, Lee JH, Hyon MS.
Ann Pharmacother. 2011 Jul;45(7-8):841-9. Epub 2011 Jun 21. Erratum in: Ann Pharmacother. 2011 Sep;45(9):1172.
Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?
Descamps OS, De Sutter J, Guillaume M, Missault L.
Atherosclerosis. 2011 Aug;217(2):308-21. Epub 2011 Jun 12. Review.
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.
Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, Wiggins KL, Bis JC, de Boer A, Maitland-van der Zee AH.
Atherosclerosis. 2011 Aug;217(2):458-64. Epub 2011 Jun 17.
SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion.
Hofnagel O, Engel T, Severs NJ, Robenek H, Buers I.
Atherosclerosis. 2011 Aug;217(2):371-8. Epub 2011 May 5.
Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.
Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, Kusano KF, Ito H.
Atherosclerosis. 2011 Aug;217(2):486-91. Epub 2011 Apr 22.
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.
Atherosclerosis. 2011 Aug;217(2):492-8. Epub 2011 Apr 27. Review.
Nox2-derived reactive oxygen species contribute to hypercholesterolemia-induced inhibition of neovascularization: effects on endothelial progenitor cells and mature endothelial cells.
Haddad P, Dussault S, Groleau J, Turgeon J, Maingrette F, Rivard A.
Atherosclerosis. 2011 Aug;217(2):340-9. Epub 2011 Apr 5.
Maternal heterozygous familial hypercholesterolemia and its consequences for mother and child.
Rutherford JD.
Circulation. 2011 Oct 11;124(15):1599-601. No abstract available.
Pregnancy outcomes in familial hypercholesterolemia: a registry-based study.
Toleikyte I, Retterstøl K, Leren TP, Iversen PO.
Circulation. 2011 Oct 11;124(15):1606-14. Epub 2011 Sep 12.
Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions.
Yang Q, Lu S, Chen Y, Song X, Jin Z, Yuan F, Li H, Zhou Y, Chen F, Huo Y.
Clin Cardiol. 2011 Jul;34(7):447-53. doi: 10.1002/clc.20909. Epub 2011 Jun 15.
Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial.
Roman MJ, Howard BV, Howard WJ, Mete M, Fleg JL, Lee ET, Devereux RB.
Hypertension. 2011 Sep;58(3):367-71. Epub 2011 Jul 25.
Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.
J Clin Endocrinol Metab. 2011 Oct;96(10):E1568-76. Epub 2011 Aug 3.
GPIHBP1 C89F neomutation and hydrophobic C-terminal domain G175R mutation in two pedigrees with severe hyperchylomicronemia.
Charrière S, Peretti N, Bernard S, Di Filippo M, Sassolas A, Merlin M, Delay M, Debard C, Lefai E, Lachaux A, Moulin P, Marçais C.
J Clin Endocrinol Metab. 2011 Oct;96(10):E1675-9. Epub 2011 Aug 3.
Standardized multidisciplinary evaluation yields significant previously undiagnosed morbidity in adult women with Turner syndrome.
Freriks K, Timmermans J, Beerendonk CC, Verhaak CM, Netea-Maier RT, Otten BJ, Braat DD, Smeets DF, Kunst DH, Hermus AR, Timmers HJ.
J Clin Endocrinol Metab. 2011 Sep;96(9):E1517-26. Epub 2011 Jul 13.
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Bays HE, Schwartz S, Littlejohn T 3rd, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK.
J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97. Epub 2011 Jul 13.
Hyoid bone-related focal carotid vasculopathy.
Renard D, Rougier M, Aichoun I, Labauge P.
J Neurol. 2011 Aug;258(8):1540-1. Epub 2011 Feb 17. No abstract available.
Cholesterol-lowering foods and reduction in serum cholesterol levels.
Weingärtner O, Böhm M, Laufs U.
JAMA. 2011 Nov 23;306(20):2217-8; author reply 2218. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on